Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2022 10:50 ET | Source: F. Hoffmann-La Roche Ltd

The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months

Two papers in The Lancet highlight one-year results from Roche’s phase III trials evaluating faricimab in neovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME)Across four...
January 12, 2022 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche launches the cobas® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care

Roche launches the cobas® pulse system, an industry first professional blood glucose management solution with mobile digital health capabilities to improve patient care Handheld blood glucose...
January 11, 2022 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche introduces cobas infinity edge, a new open digital ecosystem for point of care professionals, driving improved patient outcomes and operational efficiencies in healthcare

Roche’s new cloud-based platform connects patient test results, medical records and third-party applications, allowing professionals to monitor patients’ health, adjust treatment protocols, and make...
December 24, 2021 15:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States

Rapid test to support the American public’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test...
December 14, 2021 09:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s Polivy combination reduced the risk of disease worsening or death by 27% in people with previously untreated aggressive form of lymphoma

Polivy plus R-CHP is the first treatment regimen to significantly improve outcomes in previously untreated diffuse large B-cell lymphoma in more than 20 years, potentially transforming treatment for...
December 13, 2021 01:03 ET | Source: F. Hoffmann-La Roche Ltd

Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine

Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcarePreparing DNA for sequencing libraries is...
December 13, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A

People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to missed or delayed diagnoses of bleeding episodes and a...
December 11, 2021 08:30 ET | Source: F. Hoffmann-La Roche Ltd

Roche presents pivotal data at ASH 2021 for novel cancer immunotherapy mosunetuzumab

Results to be presented for the first time show mosunetuzumab induces high and durable complete response rates in people with follicular lymphoma who have received two or more prior therapies1New...
December 10, 2021 03:00 ET | Source: F. Hoffmann-La Roche Ltd

New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq

After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free...
December 07, 2021 04:00 ET | Source: F. Hoffmann-La Roche Ltd

Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

EMA’s CHMP recommended the approval yesterdayApproval based on results from four phase III studies in over 5,500 patientsActemra/RoActemra has also been provisionally approved in Australia for the...